» Articles » PMID: 11581298

Crystal Structure of the TRANCE/RANKL Cytokine Reveals Determinants of Receptor-ligand Specificity

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2001 Oct 3
PMID 11581298
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

RANK, the receptor activator of NF-kappaB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 A. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL. Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.

Citing Articles

Multiscale and multidisciplinary analysis of aging processes in bone.

Ravazzano L, Colaianni G, Tarakanova A, Xiao Y, Grano M, Libonati F NPJ Aging. 2024; 10(1):28.

PMID: 38879533 PMC: 11180112. DOI: 10.1038/s41514-024-00156-2.


Osteoclasts at Bone Remodeling: Order from Order.

Takito J, Nonaka N Results Probl Cell Differ. 2023; 71:227-256.

PMID: 37996681 DOI: 10.1007/978-3-031-37936-9_12.


Structural insights into the binding of zoledronic acid with RANKL computational simulations.

Wang R, Zhang W, Ma H, Zou D, Zhang Z, Wang S Front Mol Biosci. 2022; 9:992473.

PMID: 36200071 PMC: 9527314. DOI: 10.3389/fmolb.2022.992473.


Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis.

Huang D, Zhao C, Li R, Chen B, Zhang Y, Sun Z Nat Commun. 2022; 13(1):5338.

PMID: 36097003 PMC: 9468151. DOI: 10.1038/s41467-022-33006-4.


A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.

Okagu I, Ezeorba T, Aguchem R, Ohanenye I, Aham E, Okafor S Int J Mol Sci. 2022; 23(15).

PMID: 35955603 PMC: 9368769. DOI: 10.3390/ijms23158468.


References
1.
Hofbauer L, Khosla S, Dunstan C, Lacey D, Spelsberg T, Riggs B . Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999; 140(9):4367-70. DOI: 10.1210/endo.140.9.7131. View

2.
Cha S, Kim M, Choi Y, Sung B, Shin N, Shin H . 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity. 1999; 11(2):253-61. DOI: 10.1016/s1074-7613(00)80100-4. View

3.
Dougall W, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T . RANK is essential for osteoclast and lymph node development. Genes Dev. 1999; 13(18):2412-24. PMC: 317030. DOI: 10.1101/gad.13.18.2412. View

4.
Mongkolsapaya J, Grimes J, Chen N, Xu X, Stuart D, Jones E . Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol. 1999; 6(11):1048-53. DOI: 10.1038/14935. View

5.
Hymowitz S, Christinger H, Fuh G, Ultsch M, OConnell M, Kelley R . Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell. 1999; 4(4):563-71. DOI: 10.1016/s1097-2765(00)80207-5. View